Siemens acquires Bayer Diagnostics, Creates Integrated Diagnostics Powerhouse

Following upon its announcement in May that it would pay $1.86 billion for Diagnostics Products, to bring an immunodiagnostics business in-house, Siemens announced in June that it will acquire Bayer Diagnostics for approximately €4.2 billion or $5.26 billion. Siemens thus catapults itself to the number two spot in the immunodiagnostics segment of IVD, after Roche, and by its calculations, now plays a close third to Abbott Laboratories in the overall in vitro diagnostics market.

More from Archive

More from In Vivo